Cargando…
Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645484/ http://dx.doi.org/10.1186/2051-1426-3-S2-P147 |
| _version_ | 1782400822987980800 |
|---|---|
| author | Cohen, Ezra EW Moore, Kathleen N Slomovitz, Brian M Chung, Christine H Anderson, Matthew L Morris, Shannon R Mauro, David Burtness, Barbara |
| author_facet | Cohen, Ezra EW Moore, Kathleen N Slomovitz, Brian M Chung, Christine H Anderson, Matthew L Morris, Shannon R Mauro, David Burtness, Barbara |
| author_sort | Cohen, Ezra EW |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645484 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46454842015-11-20 Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer Cohen, Ezra EW Moore, Kathleen N Slomovitz, Brian M Chung, Christine H Anderson, Matthew L Morris, Shannon R Mauro, David Burtness, Barbara J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645484/ http://dx.doi.org/10.1186/2051-1426-3-S2-P147 Text en Copyright © 2015 Cohen et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Cohen, Ezra EW Moore, Kathleen N Slomovitz, Brian M Chung, Christine H Anderson, Matthew L Morris, Shannon R Mauro, David Burtness, Barbara Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer |
| title | Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer |
| title_full | Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer |
| title_fullStr | Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer |
| title_full_unstemmed | Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer |
| title_short | Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer |
| title_sort | phase i/ii study of adxs11-001 or medi4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (hpv)-positive head and neck cancer |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645484/ http://dx.doi.org/10.1186/2051-1426-3-S2-P147 |
| work_keys_str_mv | AT cohenezraew phaseiiistudyofadxs11001ormedi4736immunotherapiesaloneandincombinationinpatientswithrecurrentmetastaticcervicalorhumanpapillomavirushpvpositiveheadandneckcancer AT moorekathleenn phaseiiistudyofadxs11001ormedi4736immunotherapiesaloneandincombinationinpatientswithrecurrentmetastaticcervicalorhumanpapillomavirushpvpositiveheadandneckcancer AT slomovitzbrianm phaseiiistudyofadxs11001ormedi4736immunotherapiesaloneandincombinationinpatientswithrecurrentmetastaticcervicalorhumanpapillomavirushpvpositiveheadandneckcancer AT chungchristineh phaseiiistudyofadxs11001ormedi4736immunotherapiesaloneandincombinationinpatientswithrecurrentmetastaticcervicalorhumanpapillomavirushpvpositiveheadandneckcancer AT andersonmatthewl phaseiiistudyofadxs11001ormedi4736immunotherapiesaloneandincombinationinpatientswithrecurrentmetastaticcervicalorhumanpapillomavirushpvpositiveheadandneckcancer AT morrisshannonr phaseiiistudyofadxs11001ormedi4736immunotherapiesaloneandincombinationinpatientswithrecurrentmetastaticcervicalorhumanpapillomavirushpvpositiveheadandneckcancer AT maurodavid phaseiiistudyofadxs11001ormedi4736immunotherapiesaloneandincombinationinpatientswithrecurrentmetastaticcervicalorhumanpapillomavirushpvpositiveheadandneckcancer AT burtnessbarbara phaseiiistudyofadxs11001ormedi4736immunotherapiesaloneandincombinationinpatientswithrecurrentmetastaticcervicalorhumanpapillomavirushpvpositiveheadandneckcancer |